World Hepatitis Day, counting this year has been approved clinical domestic hepatitis B drugs.

Pharmaceutical Network Industry Dynamics, July 28 is World Hepatitis Day.China is a large country of hepatitis B, according to relevant data, there are about 70 million people living with chronic hepatitis B virus in China, of which about 20 million to 30 million are chronic hepatitis B patients.at present, the global approval of the treatment of slow hepatitis B drugs mainly interferon and nucleoside (otide) analogue two categories, but both of these categories can not effectively remove hepatitis B virus for the purpose of discontinuation of clinical treatment.to date, no drug or combination program has been approved for hepatitis B cure worldwide.facing a large group of hepatitis B patients, in recent years, the world including domestic research on new hepatitis B drugs are also continuing to advance research.this special day, the author for this year, approved clinical domestic hepatitis B drug situation made a brief inventory.HRS9950 tablets July 9 news, HengRui approved the clinical 1 new drug HRS9950 tablets start clinical, indications for chronic hepatitis B.it is known that the HRS9950 is a TLR8 elective agonist.TLR8 is one of the members of toll-like receptor, in vitro activity data show that HRS9950 has significant activation effect on human TLR8, but also indirectly activates adaptive immunity, further killing the virus infected with liver cells.HRS5091, in addition to HRS9950, HengRui's HRS5091 was approved for clinical use at the end of June this year.it is understood that HRS5091 is an assembled regulator for the hepatitis B virus shell, which can inhibit the pre-viral genome RNA, so that the hepatitis B virus assembly does not exist after the genome RNA, that is, after assembly to form an empty core.TVAX-008 Recently, the State Drug Administration Drug Review Center information shows that a therapeutic hepatitis B vaccine TVAX-008 has been officially approved to carry out human clinical trials.the drug for Nanjing Yuan competition Weixin Biopharmaceutical Co. , Ltd. developed a new type of hepatitis B in the research of new drugs, the drug type is therapeutic biological products, registered classification 1, apply for the type of new drug, on May 6, 2020.TVAX-008 is an injection for the treatment of chronic hepatitis B, and is one of the few clinically approved therapeutic hepatitis B vaccines in China.GST-HG1414, Guangshengtang announced that the company's hepatitis B treatment of the global innovative drug GST-HG141 clinical trials and research approved, marking the Phase I clinical trial program has been approved through the audit, the trial was approved to enter a substantial period of development.currently, the drug Phase I clinical trial has been identified to undertake the company and the person in charge, and in January this year held the Phase I clinical trial launch meeting, clinical trials are on the horizon.Guangshengtang said that pre-clinical studies have shown that GST-HG141 is highly safe and effective and will become the Best-in-Class project in this area, which, if further confirmed at the clinical trial stage, is expected to achieve a major breakthrough in human challenges to the cure of hepatitis B, providing a strong combination of drugs for global hepatitis B treatment.GST-HG131 Guangshengtang announced in early March this year that the company has obtained the Approval of the State Drug Administration to conduct a clinical trial of slow hepatitis B clinical trials.this is also the first approved clinical hepatitis B surface antigen (HBsAg) inhibitor.it is known that preclinical and in vivo pharmacodynamic studies have shown that GST-HG131 can induce HBV-RNA degradation, quickly significantly reduce HBsAg levels, and have good safety.in addition, on June 23, Guangshengtang in response to investors on the interactive platform mentioned that, at present, the company's hepatitis B treatment innovation drug GST-HG131 has been approved for clinical, hepatitis B treatment innovation drug GST-HG121 clinical trial application has been accepted by the State Drug Administration.the drug is a global innovation drug for hepatitis B surface antigen inhibitors (HBsAg)..